Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15008986 | 0.84 | CNR2 (0.46) | CNR2HDAC6TRPV6MEN1KMT2A | |
| SCHEMBL15013271 | 0.83 | CNR2 (0.51) | CNR2HDAC6TRPV6MEN1KMT2A | |
| SCHEMBL19524545 | 0.79 | TSHR (0.35) | CNR2HDAC6TSHR | |
| SCHEMBL1074947 | 0.75 | TRPV6 (0.61) | CNR2HDAC6TRPV6MEN1KMT2A | |
| SCHEMBL15013483 | 0.74 | CNR2 (0.36) | CNR2HDAC6TRPV6MEN1KMT2A | |
| SCHEMBL15009244 | 0.74 | CNR2 (0.62) | CNR2HDAC6TRPV6MEN1KMT2A | |
| SCHEMBL3362801 | 0.72 | HDAC6 (0.63) | CNR2HDAC6TRPV6MEN1KMT2A | |
| SCHEMBL15013498 | 0.72 | SMN1; SMN2 (0.61) | CNR2HDAC6TRPV6MEN1KMT2A | |
| SCHEMBL15009276 | 0.72 | CNR2 (0.60) | CNR2HDAC6TRPV6MEN1KMT2A | |
| SCHEMBL15013342 | 0.72 | CNR2 (0.65) | CNR2HDAC6TRPV6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3239131-A1 | NEW COMPOUNDS WITH ACTIVITY THAT PROTECTS AGAINST THE ACTION OF TOXINS AND VIRUSES IN INTRACELLULAR ACTION MODE | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2017-11-01 | — | — | EP | claimed |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | claimed |
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2016-03-24 | — | — | US | claimed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | claimed |
| EP-2145873-A1 | New compounds with activity that protects against the action of toxins and viruses in intracellular action mode | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-01-20 | — | — | EP | claimed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| EP-3239131-A1 | NEW COMPOUNDS WITH ACTIVITY THAT PROTECTS AGAINST THE ACTION OF TOXINS AND VIRUSES IN INTRACELLULAR ACTION MODE | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2017-11-01 | — | — | EP | disclosed |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-09 | — | — | US | disclosed |
| WO-2013086131-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086131-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | disclosed |
| EP-2145873-A1 | New compounds with activity that protects against the action of toxins and viruses in intracellular action mode | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | HAVCR2, MAVS, ANTXR2 | CNR2 665/4885HDAC6 1145/4885TRPV6 874/4885 |
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | HAVCR2, MAVS, ANTXR2 | CNR2 668/4885HDAC6 1240/4885TRPV6 1076/4885 |
| US-20150191439-A1 | INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A | HAVCR2, HDLBP, HSP90B1 | CNR2 4661/4885HDAC6 581/4885TRPV6 3648/4885 |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | HAVCR2, MAVS, ANTXR2 | CNR2 668/4885HDAC6 1240/4885TRPV6 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.